Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations-Reference-Cited by-同舟云学术

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Published:2016-11-30 Issue:2 Volume:7 Page:188-201
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Shin Daniel Sanghoon,Zaretsky Jesse M.,Escuin-Ordinas Helena,Garcia-Diaz Angel,Hu-Lieskovan Siwen,Kalbasi Anusha,Grasso Catherine S.,Hugo Willy,Sandoval Salemiz,Torrejon Davis Y.,Palaskas Nicolaos,Rodriguez Gabriel Abril,Parisi Giulia,Azhdam Ariel,Chmielowski Bartosz,Cherry Grace,Seja Elizabeth,Berent-Maoz Beata,Shintaku I. Peter,Le Dung T.,Pardoll Drew M.,Diaz Luis A.,Tumeh Paul C.,Graeber Thomas G.,Lo Roger S.,Comin-Anduix Begoña,Ribas Antoni

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 1028 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orchestrated metal-coordinated carrier-free celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint blockade for synergistic chemo-immunotherapy;Biomaterials;2025-01

2. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13

3. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors;Cancer Immunology, Immunotherapy;2024-09-13

4. Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer;Pharmaceutics;2024-09-07

5. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors;International Journal of Molecular Sciences;2024-09-06